Biogen announces Hong Kong has approved Leqembi to treat Alzheimer’s

Eisai (ESAIY) and Biogen (BIIB) announced that the Department of Health in Hong Kong has approved humanized anti-soluble aggregated amyloid-beta monoclonal antibody Leqembi for treatment of Alzheimer’s disease. Treatment with Leqembi should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, collectively referred to as early AD, the population in which treatment was initiated in clinical trials. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. Eisai will distribute Leqembi in Hong Kong.